ALMS

AI MemoPost-earnings T+1

Alumis

As of 2026-08-20/Post-earnings T+1/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-20 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Potentially pivotal LUMUS SLE topline data • 2026-11-18

Base target: $25 / p=45% prob

Biggest risk

The thesis remains binary and development-led. LUMUS results, regulatory execution, and eventual commercialization are unresolved, while the packet provides no verified post-print analyst target changes, estimate revisions, or detailed Aug. 19 market-reaction attribution.

Invalidation

Break below $15 or thesis failure.

What would change my mind?

The verified Q2 update strengthens the core psoriasis thesis through durable ONWARD3 efficacy and keeps the Q4 NDA target active, while Q3 LUMUS could broaden the TYK2 opportunity into SLE [#SEC-8K-2026-08-13].

Research note

Recommendation

—

Confidence

medium

As of

2026-08-20

Base target

$25

p=45%

Bull target

$40

p=25%

Bear target

$15

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Post-earnings uncertainty remains a near-term overhang
ONWARD3 data support psoriasis launch optionality
A-005 Parkinson’s biomarker trial

BearKey bullets

A-005 and additional indications remain early-stage and subject to disciplined capital allocation.
LUMUS SLE topline data may fail to demonstrate sufficient efficacy or safety.
NDA timing, regulatory review, approval, labeling, and commercial launch remain uncertain.

WatchKey bullets

Potentially pivotal LUMUS SLE topline data

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+1

Base case: $25 (p=45%)

Target spread vs base: +60% / -40%

Scenario probabilities

Bull Target: $40 (p=25%)Base Target: $25 (p=45%)Bear Target: $15 (p=30%)

Commentary

Primary-source evidence is constructive on clinical validation and milestone timing, but forward visibility remains limited. The latest verified earnings-related company source is the Aug. 13 8-K [#SEC-8K-2026-08-13]; the scheduled Aug. 19 follow-up lacks confirmed analyst revisions or a separate company transcript in the packet. Deterministic returns are negative across the 5-day through 120-day horizons, supporting a monitoring stance rather than a momentum chase. Social coverage is unavailable.

As of 2026-08-20 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Post-earnings uncertainty remains a near-term overhang
ONWARD3 data support psoriasis launch optionality
A-005 Parkinson’s biomarker trial

Scenarios

Bull Target (Scenario probability)

$40 / p=25% prob

Base Target (Scenario probability)

$25 / p=45% prob

Bear Target (Scenario probability)

$15 / p=30% prob

Analysis 2026-08-20 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-11-18
Potentially pivotal LUMUS SLE topline data
Alumis anticipates Phase 2b LUMUS topline data in systemic lupus erythematosus during Q3 2026, creating a binary franchise-expansion event [#SEC-8K-2026-08-13].
Prob 60.00% • Move 25.00% • Priced-in 35.00%
EVENT2026-11-18
Psoriasis NDA submission target
Management remains on track to submit an FDA NDA for envudeucitinib in moderate-to-severe plaque psoriasis in Q4 2026 [#SEC-8K-2026-08-13].
Prob 75.00% • Move 15.00% • Priced-in 50.00%

Short-term Catalysts

Next few weeks

Post-earnings uncertainty remains a near-term overhang
2026-11-18
The scheduled T+1 earnings follow-up has no separate verified Aug. 19 company release, transcript, or analyst-revision evidence in the packet; the latest confirmed operating update is the Aug. 13 Q2 8-K [#SEC-8K-2026-08-13].
Prob 55% • Move -8% • Priced-in 35%

Long-term Catalysts

Months to a year

ONWARD3 data support psoriasis launch optionality
2027-08-20
ONWARD3 reported 75% PASI 90 and 54% PASI 100 responses after up to 48 weeks in 773 patients, with safety described as consistent with prior studies [#SEC-8K-2026-08-13].
Prob 70% • Move 18% • Priced-in 65%
A-005 Parkinson’s biomarker trial
2027-08-20
Alumis plans to initiate a Phase 2 biomarker trial for its CNS-penetrant TYK2 inhibitor A-005 in Parkinson’s disease in the first half of 2027, subject to execution and capital allocation [#SEC-8K-2026-08-13].
Prob 45% • Move 10% • Priced-in 15%

Risks

A-005 and additional indications remain early-stage and subject to disciplined capital allocation.
LUMUS SLE topline data may fail to demonstrate sufficient efficacy or safety.
NDA timing, regulatory review, approval, labeling, and commercial launch remain uncertain.
Post-earnings analyst revisions, consensus surprise data, and verified market-reaction attribution are unavailable.
The stock remains dependent on binary clinical and regulatory milestones rather than established commercial revenue.

Peers

Symbol	Summary
ARQT	Closest provided dermatology-biotech comparison and useful for framing psoriasis commercialization expectations; still not a like-for-like TYK2 valuation comp.
CLDX	Same-sector near-cap biopharma candidate; useful mainly for broad clinical-biotech risk and valuation context.
MBX	Same-sector near-cap biotech candidate; indication and program differences make it a loose comparator.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-20

Loading AI feed…

Symbol

Summary

ARQT

Closest provided dermatology-biotech comparison and useful for framing psoriasis commercialization expectations; still not a like-for-like TYK2 valuation comp.

CLDX

Same-sector near-cap biopharma candidate; useful mainly for broad clinical-biotech risk and valuation context.

MBX

Same-sector near-cap biotech candidate; indication and program differences make it a loose comparator.